Dengue virus serotype 3 genome (DENV-3 genome)

The Dengue virus serotype 3 (DENV-3) genome is a single-stranded, positive-sense RNA molecule of approximately 11 kilobases that serves as the fundamental blueprint for viral replication and protein synthesis (NCBI, 2023). It contains a single open reading frame encoding a polyprotein that is post-translationally cleaved into three structural proteins (C, prM, E) and seven non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, NS5) (UniProt, 2024). The genome functions as a template for the synthesis of negative-strand RNA, which in turn serves as a template for new genomic RNA, a process mediated by the viral RNA-dependent RNA polymerase (NS5) (Nature Reviews Microbiology, 2021). As a therapeutic target, the DENV-3 genome is addressed through direct-acting antivirals such as nucleoside analogs (e.g., Balapiravir) that induce premature chain termination during replication (PubMed, 2022). Additionally, novel strategies like RNA interference (RNAi) and antisense oligonucleotides are being explored to directly degrade or block the translation of the viral RNA (Journal of Virology, 2023). Infection with DENV-3 can result in a range of clinical outcomes from mild Dengue fever to life-threatening Dengue Hemorrhagic Fever and Dengue Shock Syndrome (WHO, 2023). Therapeutic challenges include the high mutation rate of the RNA genome, which facilitates the emergence of drug-resistant strains, and the risk of antibody-dependent enhancement (ADE) in heterologous secondary infections (StatPearls, 2024).

Other names

Dengue virus serotype 3 RNADENV-3 genomic RNADengue virus type 3 polyprotein geneDENV3 genome

Inhibition of viral RNA synthesis through RNA-dependent RNA polymerase (RdRp) inhibition, premature RNA chain termination by nucleoside analogs, and sequence-specific degradation via RNA interference (RNAi) or antisense oligonucleotides.